On the mechanism of papaverine action on the control of vascular smooth muscle contractile activity by extracellular calcium

1971 ◽  
Vol 23 (9) ◽  
pp. 712-713 ◽  
Author(s):  
F. Demesy ◽  
J. C. Stoclet
Author(s):  
Olena M. Semenykhina ◽  
Olga V. Bazilyuk ◽  
Yulia P. Korkach ◽  
Vadim F. Sagach

2019 ◽  
Vol 141 (3) ◽  
Author(s):  
Alexander W. Caulk ◽  
Jay D. Humphrey ◽  
Sae-Il Murtada

Vascular smooth muscle cells (VSMCs) can regulate arterial mechanics via contractile activity in response to changing mechanical and chemical signals. Contractility is traditionally evaluated via uniaxial isometric testing of isolated rings despite the in vivo environment being very different. Most blood vessels maintain a locally preferred value of in vivo axial stretch while subjected to changes in distending pressure, but both of these phenomena are obscured in uniaxial isometric testing. Few studies have rigorously analyzed the role of in vivo loading conditions in smooth muscle function. Thus, we evaluated effects of uniaxial versus biaxial deformations on smooth muscle contractility by stimulating two regions of the mouse aorta with different vasoconstrictors using one of three testing protocols: (i) uniaxial isometric testing, (ii) biaxial isometric testing, and (iii) axially isometric plus isobaric testing. Comparison of methods (i) and (ii) revealed increased sensitivity and contractile capacity to potassium chloride and phenylephrine (PE) with biaxial isometric testing, and comparison of methods (ii) and (iii) revealed a further increase in contractile capacity with isometric plus isobaric testing. Importantly, regional differences in estimated in vivo axial stretch suggest locally distinct optimal biaxial configurations for achieving maximal smooth muscle contraction, which can only be revealed with biaxial testing. Such differences highlight the importance of considering in vivo loading and geometric configurations when evaluating smooth muscle function. Given the physiologic relevance of axial extension and luminal pressurization, we submit that, when possible, axially isometric plus isobaric testing should be employed to evaluate vascular smooth muscle contractile function.


1999 ◽  
Vol 83 (1) ◽  
pp. 75-80 ◽  
Author(s):  
Shaun A. Price ◽  
David A. Spain ◽  
Mark A. Wilson ◽  
Patrick D. Harris ◽  
R.Neal Garrison

1994 ◽  
Vol 56 (6) ◽  
pp. 556-561 ◽  
Author(s):  
Samuel H. Wurster ◽  
Ping Wang ◽  
Richard E. Dean ◽  
Irshad H. Chaudry

2006 ◽  
Vol 348 (4) ◽  
pp. 1215-1223 ◽  
Author(s):  
Sanela Smajilovic ◽  
Jakob Lerche Hansen ◽  
Tue E.H. Christoffersen ◽  
Ewa Lewin ◽  
Søren P. Sheikh ◽  
...  

2010 ◽  
Vol 88 (8) ◽  
pp. 840-849 ◽  
Author(s):  
Faquan Liang ◽  
Christopher B. Glascock ◽  
Denise L. Schafer ◽  
Jennifer Sandoval ◽  
LouAnn Cable ◽  
...  

Endothelin is a potent vasoconstrictor often up-regulated in hypertension. Endothelin vasoconstriction is mediated via the G-protein coupled endothelin A (ETA) receptor present on vascular smooth muscle. Endothelin receptor antagonists (ERAs) have been shown to antagonize ET-induced vasoconstriction. We describe the primary pharmacology of darusentan, a propanoic acid based ERA currently in phase 3 clinical trials for resistant hypertension. Darusentan was tested in membrane-, cell-, and tissue-based assays to determine its biochemical and functional potency. Rat aortic vascular smooth muscle cells (RAVSMs) were characterized using flow cytometry. RAVSM membrane fractions tested in saturation experiments exhibited moderate endothelin receptor density. Receptor counting revealed that >95% of the endothelin receptors in these fractions were the ETA subtype. (S)-Darusentan competed for radiolabeled endothelin binding in RAVSM membranes with single-site kinetics, exhibiting a Ki = 13 nmol/L. (R)-Darusentan exhibited no binding activity. In cultured RAVSMs, endothelin induced increases in inositol phosphate and Ca2+ signaling, both of which were attenuated by (S)-darusentan in a concentration-dependent manner. In isolated endothelium-denuded rat aortic rings, (S)-darusentan inhibited endothelin-induced vascular contractility with a pA2 = 8.1 ± 0.14 (n = 4 animals; mean ± SD). (R)-Darusentan had no effect. The vasorelaxant potency of (S)-darusentan did not change when determined in isolated denuded rat mesenteric arterioles, suggesting a similar mode of action in both conductance and resistance arteries. In vascular smooth muscle, (S)-darusentan is an ERA with high affinity for the ET receptor, which in this preparation is predominantly ETA receptors. (S)-Darusentan inhibits endothelin-induced signaling related to pro-contractile activity and is a potent inhibitor of vasoconstriction in large and small arteries.


2010 ◽  
Vol 9 (6) ◽  
pp. 12-17
Author(s):  
M. B. Baskakov ◽  
S. V. Gusakova ◽  
A. S. Zheludeva ◽  
L. V. Smagly ◽  
I. V. Kovalyov ◽  
...  

In preparations of rat aorta, used as a model of muscular type arteries, the method mehanografii studied the effect of hydrogen sulfide on the reduction of isolated of vascular smooth muscle. Found that hydrogen sulfide in concentrations 1—50 mmol increases the mechanical stress of smooth muscle in high-K + medium. At higher concentrations (300—1 000 mmol) H2S leads to lower amplitude giperkalievoy contraction in high-K + medium. Reduction of smooth muscle cells caused by phenylephrine inhibited the action of hydrogen sulfide in the whole range of concentrations. The causes of differences in data obtained with the results of studies in other laboratories, and possible mechanisms of action of hydrogen sulfide on the contractile activity of vascular smooth muscle.


Sign in / Sign up

Export Citation Format

Share Document